Results 71 to 80 of about 571,282 (185)

IDH-wildtype secondary glioblastoma arising in IDH-mutant diffuse astrocytoma: a case report

, 2020
Primary glioblastoma develops de novo without clinical or histological evidence of a low-grade precursor lesion, whereas secondary glioblastoma develops from a low-grade glioma. The present report describes an extraordinary case of IDH-wildtype secondary
Nak-Jung Kwon (439483), Gheeyoung Choe (570126), Chae‑Yong Kim (9557009), Byul-Hee Yoon (9557000), Kyu Sang Lee (9557006), Ju Sang Park (9557003), Seongmin Kang (8881781)   +6 more
core   +1 more source

RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion

BMC Bioinformatics, 2019
Background Accurate classification of diffuse gliomas, the most common tumors of the central nervous system in adults, is important for appropriate treatment.
Sean Chun-Chang Chen, Chung-Ming Lo, Shih-Hua Wang, Emily Chia-Yu Su   +3 more
doaj   +1 more source

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review. [PDF]

Mol Oncol
In 2021, Suwala et al. described Primary Mismatch Repair Deficient IDH‐mutant Astrocytoma (PMMRDIA) as a distinct group of gliomas. In unsupervised clustering, PMMRDIA forms distinct cluster, separate from other IDH‐mutant gliomas, including IDH‐mutant ...
Ahmad O, Ahmad T, Pfister SM.
europepmc   +2 more sources

Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2–4 glioma patients: a deep Radiomics Approach [PDF]

BMC Med Imaging
Background The role of isocitrate dehydrogenase (IDH) mutation status for glioma stratification and prognosis is established. While structural magnetic resonance image (MRI) is a promising biomarker, it may not be sufficient for non-invasive ...
Yuan J, Siakallis L, Li H, Brandner S, Zhang J, Li C, Mancini L, Bisdas S.   +7 more
europepmc   +2 more sources

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies

Cancer Medicine, 2022
Background Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma.
Shuchen Chen, Honglin Zhu, Meizi Jin, Hongling Yuan, Zhenzhen Liu, Jielin Li, Xiang Zhang, Lihui Meng, Ting Li, Yuzhu Diao, Hong Gao, Chengyu Hong, Xinjiang Zhu, Jian Zheng, Fei Li, Yanling Niu, Tonghui Ma, Xiaoling Li   +17 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

ADC maps in non invasive characterization of IDH mutation status in high grade glioma

, 2018
Introduction The new brain tumor classification (2016 WHO) distinguishes diffuse glioma based on their molecular characteristics of isocitrate dehydroge- nase (IDH) in IDH-mutant, IDH-wild type and IDH NOS (not otherwise specified). The evaluation of IDH
Porretti G, Mattiuzzi A, Piccinini S., Gatti F, Feraco P   +4 more
core   +1 more source

Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase‐mutant lower‐grade gliomas

Annals of Clinical and Translational Neurology
Objective To differentiate glioma grading and determine isocitrate dehydrogenase (IDH) mutation status, which are crucial for prognosis assessment and treatment planning in glioma patients.
Dongxu Zhao, Lin Duan, Tareq A. Juratli, Fazheng Shen, Liyun Zhou, Shulin Cui, Hang Zhang, Hang Ren, Luyao Cheng, Hailan Wang, Wenhan Shi, Tianxiao Li, Ming Li   +12 more
doaj   +1 more source

Proteomic and Metabolomic Profiling Reveal Mitochondrial Transplantation–Mediated Reprogramming in Gastric Cancer Cells

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Mitochondria provide multiple functions for cellular physiology. Transplantation of mitochondria isolated from gastric epithelial cells GES‐1 reducing the malignancy of gastric cancer cells AGS was previously reported. To elucidate the underlying mechanisms, TMT‐based proteomic analysis coupling ingenuity pathway software prediction revealed ...
Ping‐Chen Chen, Chen‐Kai Liu, Ching‐Chung Tsai, Erna Sulistyowati, Fu‐An Li, Chung‐Jung Liu, Deng‐Chyang Wu, Shih‐Hsuan Chou, Fu‐Chen Kuo, Bin Huang   +9 more
wiley   +1 more source